That said, we deeply appreciate again the interest and hope that this study has sparked and we will work to inform you ASAP on the protocol as soon as we get through the IND process with FDA. Thank you all 🙏🏻 /end
before the protocol is fully confirmed. I’m sure many people have thoughts and lived experience about dosages and protocol, but when we’re starting something new like this we have to follow guidance from studies that have gone before, so that is what we’re doing right now. 2/
Thanks everyone for the excitement and questions about our rapamycin trial for #LongCOVID. We will definitely share a protocol as soon as we can on the regular channels (clinical https://t.co/Du6GtdZqVy, etc), but we are still waiting on some clearances from regulatory bodies 1/
When I tell this story, all Americans 🇺🇸 and most British 🇬🇧 don’t believe me.
Italy 🇮🇹 cannot have startups by design. This is due many items, starting with the untranslable “studio di settore”.
The 🇮🇹 tax authorities assume that given x company assets you MUST make a profit 1/5
Researchers provide an important clue to Long Covid, finding viral proteins in the blood of 25% of people > 1 year after infection. Team at UCSF led by @MichaelPelusoMD and supported by Amy Proal @microbeminded2 of @polybioRF#LongCovid#longcovidkids
https://t.co/nAgBZhk0o4
Our new @UCSF#FindCOVID/#LIINC paper in @NatureComms showing SCV2 burden in first 3 weeks of COVID predicts future #LongCovid.
In addition to LC treatment trials, we need investment in studies to prevent LC! Zero US-based trials on prevention so far.
https://t.co/mT0cLdySV8
Excited to be visiting @VirusesImmunity at the 2nd @YaleCII symposium today to talk about #LongCovid - Where we are, where we need to go, and how we can get there.
@devilslayerr_@jasminericegirl I see what you are saying, but it doesn't work. You are using good test taking logic to eliminate A and D, since neither can be correct if there is only one correct answer. But the task is defined as choosing *randomly*, so your test taking logic is not allowed.
Our mechanistic review of #LongCovid - published in @CellCellPress - hopefully will be helpful coming out of the very inspiring RECOVER-Treating Long COVID meeting this week.
Excited for the progress we will make together in the next year!
https://t.co/JUYQnXYRlO
The preventable loss of a family-owned neighborhood small business, the kind of place San Francisco supposedly cares about. What say you, @MattHaneySF and @LondonBreed ? https://t.co/QkkW7VeoDv
Everyone still underestimates Paul Graham's theory that the more charismatic presidential candidate always wins, which has held true in every US election since they started doing televised debates in 1960 (with very rare exceptions)
https://t.co/AvDcDdhTnm
@BeschlossDC Coronations are bad for the candidate and bad for the process. If the Democratic party had had a competitive primary process in the first place, it wouldn't be in the crisis it finds itself in today. Time for the #CarvillePlan
https://t.co/QPIqIYk793
New @UCSF#LIINC paper: immune activation & viral persistence in tissue up to 2 years post-COVID. Found double-stranded RNA in #LongCOVID, suggesting active reservoir persists and evades immune clearance. Thanks @polybioRF, @NIH for support. @ScienceTM
https://t.co/30Eb0juBN7